Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation
WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.
You may also be interested in...
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.